Search

Your search keyword '"Amy Fothergill"' showing total 3 results
Start Over Author "Amy Fothergill" Journal mmwr. morbidity and mortality weekly report
3 results on '"Amy Fothergill"'

1. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022

Author

Jennifer L, Farrar, Nathaniel M, Lewis, Kennedy, Houck, Michelle, Canning, Amy, Fothergill, Amanda B, Payne, Adam L, Cohen, Joshua, Vance, Bridget, Brassil, Erin, Youngkin, Bailey, Glenn, Anil, Mangla, Nikki, Kupferman, Katharine, Saunders, Cristina, Meza, Dawn, Nims, Susan, Soliva, Brandon, Blouse, Tiffany, Henderson, Emily, Banerjee, Brooklyn, White, Rachael, Birn, Anna M, Stadelman, Meaghan, Abrego, Meagan, McLafferty, Michael G, Eberhart, Michael, Pietrowski, Sandra Miranda, De León, Emma, Creegan, Abdoulaye, Diedhiou, Caleb, Wiedeman, Jade, Murray-Thompson, Elizabeth, McCarty, Jessica, Marcinkevage, Anna, Kocharian, Elizabeth A, Torrone, Logan C, Ray, Daniel C, Payne, and Rachel, Klos

Subjects
Male, Vaccines, Health (social science), Health Information Management, Epidemiology, Health, Toxicology and Mutagenesis, Vaccinia, Humans, General Medicine, United States, Smallpox Vaccine, Demography
Abstract

As of November 14, 2022, monkeypox (mpox) cases had been reported from more than 110 countries, including 29,133 cases in the United States.* Among U.S. cases to date, 95% have occurred among males (1). After the first confirmed U.S. mpox case on May 17, 2022, limited supplies of JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) were made available to jurisdictions for persons exposed to mpox. JYNNEOS vaccine was approved by the Food and Drug Administration (FDA) in 2019 as a 2-dose series (0.5 mL per dose, administered subcutaneously) to prevent smallpox and mpox disease.

Published
2022

2. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022

Author

Amanda B. Payne, Logan C. Ray, Matthew M. Cole, Michelle Canning, Kennedy Houck, Hazel J. Shah, Jennifer L. Farrar, Nathaniel M. Lewis, Amy Fothergill, Elizabeth B. White, Leora R. Feldstein, Lauren E. Roper, Florence Lee, Jennifer L. Kriss, Emily Sims, Ian H. Spicknall, Yoshinori Nakazawa, Adi V. Gundlapalli, Tom Shimabukuro, Adam L. Cohen, Margaret A. Honein, Jonathan Mermin, and Daniel C. Payne

Subjects
Health (social science), Health Information Management, Epidemiology, Health, Toxicology and Mutagenesis, General Medicine
Abstract

As of October 28, 2022, a total of 28,244* monkeypox (mpox) cases have been reported in the United States during an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), administered subcutaneously as a 2-dose (0.5 mL per dose) series (with doses administered 4 weeks apart), was approved by the Food and Drug Administration (FDA) in 2019 to prevent smallpox and mpox disease (2); an FDA Emergency Use Authorization issued on August 9, 2022, authorized intradermal administration of 0.1 mL per dose, increasing the number of persons who could be vaccinated with the available vaccine supply

Published
2022

3. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022

Author

Amanda B. Payne, Logan C. Ray, Kiersten J. Kugeler, Amy Fothergill, Elizabeth B. White, Michelle Canning, Jennifer L. Farrar, Leora R. Feldstein, Adi V. Gundlapalli, Kennedy Houck, Jennifer L. Kriss, Nathaniel M. Lewis, Emily Sims, Dawn K. Smith, Ian H. Spicknall, Yoshinori Nakazawa, Inger K. Damon, Amanda C. Cohn, and Daniel C. Payne

Subjects
Male, Sexual and Gender Minorities, Health (social science), Health Information Management, Epidemiology, Health, Toxicology and Mutagenesis, Incidence, Humans, General Medicine, Monkeypox, Homosexuality, Male, Smallpox Vaccine, United States
Abstract

Human monkeypox is caused by Monkeypox virus (MPXV), an Orthopoxvirus, previously rare in the United States (1). The first U.S. case of monkeypox during the current outbreak was identified on May 17, 2022 (2). As of September 28, 2022, a total of 25,341 monkeypox cases have been reported in the United States.* The outbreak has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) (3). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), administered subcutaneously as a 2-dose (0.5 mL per dose) series with doses administered 4 weeks apart, was approved by the Food and Drug Administration (FDA) in 2019 to prevent smallpox and monkeypox infection (4). U.S. distribution of JYNNEOS vaccine as postexposure prophylaxis (PEP) for persons with known exposures to MPXV began in May 2022. A U.S. national vaccination strategy

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results